The FDA assigned a PDUFA target action date of February 28, 2027 If approved, AD109 has the potential to become the first oral pharmacologic therapy designed to address the neuromuscular root cause of upper airway collapse for the millions of people living with OSA July 14, 2026 -- Apnimed, Inc., a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, t

July 14, 2026-- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical study evaluating a cadonilimab-based combination regimen for the perioperative treatment of locally advanced, resectable HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. Cadonilimab is the world's first PD-1/CTLA-4 bispecific antibody developed by Akeso. The study is be

A year after emerging from stealth, Draig Therapeutics has closed an oversubscribed $65-million series B that will go toward accelerating its neuropsychiatric drug pipeline, with depression treatment DT-101 leading the charge. DT-101 is a positive allosteric modulator of the AMPA receptor that is being evaluated for major depressive disorder (MDD). The drug is currently being studied in two Phase II trials: a global study assessing DT-101 as monotherapy and a US study testing it in the adjunct

Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset and expert team strengthen Servier's commitment to innovate for patients with high unmet medical needs. July 13, 2026 -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the muscular dystrophy business of Edgewise The

GSK reported positive data Friday from a B7-H3-targeting asset partnered with Hansoh Pharmaceutical Group Co. The Phase III ARTEMIS-008 trial run in China is testing the antibody-drug conjugate (ADC) risvutatug rezetecan (ris-rez) and has succeeded on its primary endpoint of overall survival (OS) in patients with advanced or relapsed small-cell lung cancer (SCLC), the UK drugmaker said. Hansoh will use the results to back its request for regulatory approval in China. GSK acquired ex-China righ

Funding to advance MindRank’s AI-native drug R&D engine and innovative pipeline, including MDR-001, an oral small-molecule GLP-1 receptor agonist in Phase III clinical development in China July 09, 2026 -- MindRank AI Ltd. (“MindRank”), a clinical-stage biotechnology company dedicated to building an AI-native engine for drug research and development, today announced the completion of a $52 million Series B financing. The round was led by a group of institutional and healthcare funds. MindRank

Application based on long-term safety and efficacy data from three ongoing studies, including adult height and additional clinical outcomes beyond linear growth, including body proportionality and arm span evaluated over long-term follow-up FDA PDUFA target action date of Feb. 28, 2027 July 13, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for V

Boehringer Ingelheim’s Jascayd (nerandomilast) tablets have been granted marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF). Jascayd is the first treatment of its kind licensed for use in IPF and PPF in adults. The MHRA authorisation is based on the results of the pivotal phase 3 clinical trials involving 1,177 and 1,176 patients with IPF and PPF r

July 10, 2026 -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced that the Company has submitted an Orphan Drug Designation (ODD) request to the U.S. Food and Drug Administration (FDA) for its Gamma Delta T (GDT) cell therapy product, Vdelta2+ Gamma Delta T Cells, for the treatment of glioblastoma multiforme (GBM). The FDA's Office of Orphan Produ

July 13, 2026 -- Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, today announced that the first participant has been dosed in its Phase 1 clinical trial of DX-104 in China. DX-104 is an innovative Group B meningococcal (MenB) vaccine candidate developed using the company's proprietary OMV Plus® platform. This milestone marks a significant step in the concurrent global development of DX-104, following the initiation and ongoing progre